Saltar al contenido

FDA Requires a Warning About Rare Vision Loss (NAION) on All GLP-1 Drugs, From Ozempic and Wegovy to Mounjaro and Zepbound

10 de noviembre de 2026 · 7 min

Notas del episodio

On November 9, 2026, the US Food and Drug Administration said it is requiring the makers of all GLP-1 receptor agonist medicines, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Foundayo, to add information to the Warnings and Precautions section of their labels about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden, painless vision loss in one eye, including permanent vision loss. In an FDA analysis of 126 randomized trials with 134,253 patients, there were 10 probable NAION cases among people on GLP-1 drugs and 5 among people on placebo, or 6.4 versus 3.8 cases per 100,000 person-years. An FDA Sentinel study in adults with type 2 diabetes found a higher risk with GLP-1 drugs than with DPP-4 inhibitors but no statistically significant difference compared with SGLT2 inhibitors, and FDA's review of animal data did not identify a mechanism. FDA describes the risk as potential. We also cover the 2024 JAMA Ophthalmology study that prompted FDA's review, the European Medicines Agency's June 2025 conclusion that NAION is a very rare side effect of semaglutide, and statements from Novo Nordisk and Eli Lilly.

Sources

  • FDA Drug Safety Communication (Nov 9, 2026), labeling changes for GLP-1 receptor agonists due to potential increased risk of NAION: fda.gov
  • Reuters (Nov 9, 2026), US FDA orders new eye risk warnings for Ozempic, Zepbound: investing.com
  • Bloomberg (Nov 9, 2026), FDA adds warning label to obesity drugs for eye condition, with Novo Nordisk and Lilly statements: ndtvprofit.com
  • Healio (Nov 9, 2026), FDA to require NAION risk warning for GLP-1 therapies: healio.com
  • European Medicines Agency (June 6, 2025), PRAC concludes NAION is a very rare side effect of semaglutide medicines: ema.europa.eu
  • JAMA Ophthalmology (2024), Hathaway et al., risk of NAION in patients prescribed semaglutide (PubMed abstract): pubmed.ncbi.nlm.nih.gov

Cover: original code-generated illustration (no photo).

This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.

Visit glp1newspaper.com for today's stories and free email alerts.

Todos los episodios de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Ajustes

Visualización

Idioma

Determina qué emisoras ves primero en la página de inicio.

Historial

Las emisoras y episodios escuchados recientemente y tus últimas búsquedas solo se guardan en este navegador.

Avisos

Un breve aviso cuando un pódcast que sigues tiene un episodio nuevo. Puedes desactivar pódcast concretos con la campana de su página.

Cuenta

Guarda tus favoritos: en la app y en la web.

Atajos de teclado

/
Abrir búsqueda
Espacio
Reproducir o pausar
← →
En el reproductor: 15 s atrás, 30 s adelante (episodios) · en una fila: siguiente tarjeta
↑ ↓
En una fila: destino dentro de la tarjeta
Inicio / Fin
En una fila: primera o última tarjeta
Esc
Cerrar ventana o menú
?
Este resumen
Reproduciendo ahora

Ir a la emisora

A continuación

    Añade episodios con «A continuación»: sonarán después del episodio actual.